KBC Group
ADVM

KBC Group’s Adverum Biotechnologies ADVM Stock Holding History

KBC Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-420
Closed -$14K – 1290
2021
Q2 		$14K Hold
420
– – ﹤0.01% 1268
2021
Q1 		$42K Buy
420
+400
+2,000% +$48K ﹤0.01% 1276
2020
Q4 		$12K Hold
20
– – ﹤0.01% 1259
2020
Q3 		$2K Hold
20
– – ﹤0.01% 1223
2020
Q2 		$4K Buy
20
+10
+100% +$1.77K ﹤0.01% 1264
2020
Q1 		$1K Hold
10
– – ﹤0.01% 1272
2019
Q4 		$1K Sell
10
-11
-52% -$970 ﹤0.01% 1489
2019
Q3 		$1K Sell
21
-199
-90% -$22.4K ﹤0.01% 1474
2019
Q2 		$26K Hold
220
– – ﹤0.01% 1400
2019
Q1 		$12K Hold
220
– – ﹤0.01% 1389
2018
Q4 		$7K Hold
220
– – ﹤0.01% 1296
2018
Q3 		$13K Hold
220
– – ﹤0.01% 1380
2018
Q2 		$12K Hold
220
– – ﹤0.01% 1275
2018
Q1 		$13K Buy
+220
New +$13.7K ﹤0.01% 1258

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KBC Group's ADVM Position: Q3 2021 in Review

KBC Group sold out of Adverum Biotechnologies (ADVM) in Q3 2021, closing a stake of 420 shares — an estimated $14K sold.

KBC Group first reported a position in ADVM in Q1 2018 and held it in 14 quarters. The position peaked at $42K in Q1 2021. 110 funds tracked by Wall St. Rank hold ADVM as of Q3 2021.

  • KBC Group reported no remaining Adverum Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • KBC Group sold 420 Adverum Biotechnologies shares in Q3 2021, an estimated $14K.
  • KBC Group first reported a position in Adverum Biotechnologies in Q1 2018 and held it in 14 quarters.
  • KBC Group's Adverum Biotechnologies position peaked at $42K in Q1 2021.
  • 110 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2021.

Based on KBC Group's 13F filing for Q3 2021, filed 10 Nov 2021.